Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003

Mitsuo Kusano, Michitaka Honda, Koji Okabayashi, Koho Akimaru, Syuichi Kino, Yasushige Tsuji, Masashi Watanabe, Satoshi Suzuki, Takaki Yoshikawa, Junichi Sakamoto, Koji Oba, Shigetoyo Saji

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy. Methods: Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF). The primary endpoint was overall survival (OS). Results: In the WHF group, the cumulative failure rate of hepatic arterial catheterization was 16.7% at 6 months. The occurrence of grade 3 adverse events was comparable between the groups. The 5-year OS rates were 59.0% in the CVI group and 34.9% in the WHF group (P = 0.164). CVI tended to show a protective effect against liver metastasis regarding the 5-year liver-specific cumulative recurrence rate: CVI, 45.0% vs. WHF, 68.3%; P = 0.037). Conclusion: HAI therapy has a certain protective effect against liver metastasis after curative resection in patients with colorectal cancer. However, this therapy did not contribute to any marked improvement in their overall survival.

Original languageEnglish
Pages (from-to)84-90
Number of pages7
JournalJournal of Cancer Research and Therapeutics
Volume13
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Drug Therapy
Liver
Fluorouracil
Survival
Liver Failure
Catheterization
Colon
Survival Rate
Carcinoma
Recurrence
Therapeutics

Keywords

  • Adjuvant chemotherapy
  • Colorectal cancer
  • Hepatic arterial infusion
  • Liver metastasis
  • Prognosis

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma : JFMC 29-0003. / Kusano, Mitsuo; Honda, Michitaka; Okabayashi, Koji; Akimaru, Koho; Kino, Syuichi; Tsuji, Yasushige; Watanabe, Masashi; Suzuki, Satoshi; Yoshikawa, Takaki; Sakamoto, Junichi; Oba, Koji; Saji, Shigetoyo.

In: Journal of Cancer Research and Therapeutics, Vol. 13, No. 1, 01.01.2017, p. 84-90.

Research output: Contribution to journalArticle

Kusano, Mitsuo ; Honda, Michitaka ; Okabayashi, Koji ; Akimaru, Koho ; Kino, Syuichi ; Tsuji, Yasushige ; Watanabe, Masashi ; Suzuki, Satoshi ; Yoshikawa, Takaki ; Sakamoto, Junichi ; Oba, Koji ; Saji, Shigetoyo. / Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma : JFMC 29-0003. In: Journal of Cancer Research and Therapeutics. 2017 ; Vol. 13, No. 1. pp. 84-90.
@article{b1fab9ca965941e396738502f153ecde,
title = "Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003",
abstract = "Background: The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy. Methods: Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF). The primary endpoint was overall survival (OS). Results: In the WHF group, the cumulative failure rate of hepatic arterial catheterization was 16.7{\%} at 6 months. The occurrence of grade 3 adverse events was comparable between the groups. The 5-year OS rates were 59.0{\%} in the CVI group and 34.9{\%} in the WHF group (P = 0.164). CVI tended to show a protective effect against liver metastasis regarding the 5-year liver-specific cumulative recurrence rate: CVI, 45.0{\%} vs. WHF, 68.3{\%}; P = 0.037). Conclusion: HAI therapy has a certain protective effect against liver metastasis after curative resection in patients with colorectal cancer. However, this therapy did not contribute to any marked improvement in their overall survival.",
keywords = "Adjuvant chemotherapy, Colorectal cancer, Hepatic arterial infusion, Liver metastasis, Prognosis",
author = "Mitsuo Kusano and Michitaka Honda and Koji Okabayashi and Koho Akimaru and Syuichi Kino and Yasushige Tsuji and Masashi Watanabe and Satoshi Suzuki and Takaki Yoshikawa and Junichi Sakamoto and Koji Oba and Shigetoyo Saji",
year = "2017",
month = "1",
day = "1",
doi = "10.4103/0973-1482.184524",
language = "English",
volume = "13",
pages = "84--90",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma

T2 - JFMC 29-0003

AU - Kusano, Mitsuo

AU - Honda, Michitaka

AU - Okabayashi, Koji

AU - Akimaru, Koho

AU - Kino, Syuichi

AU - Tsuji, Yasushige

AU - Watanabe, Masashi

AU - Suzuki, Satoshi

AU - Yoshikawa, Takaki

AU - Sakamoto, Junichi

AU - Oba, Koji

AU - Saji, Shigetoyo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy. Methods: Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF). The primary endpoint was overall survival (OS). Results: In the WHF group, the cumulative failure rate of hepatic arterial catheterization was 16.7% at 6 months. The occurrence of grade 3 adverse events was comparable between the groups. The 5-year OS rates were 59.0% in the CVI group and 34.9% in the WHF group (P = 0.164). CVI tended to show a protective effect against liver metastasis regarding the 5-year liver-specific cumulative recurrence rate: CVI, 45.0% vs. WHF, 68.3%; P = 0.037). Conclusion: HAI therapy has a certain protective effect against liver metastasis after curative resection in patients with colorectal cancer. However, this therapy did not contribute to any marked improvement in their overall survival.

AB - Background: The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy. Methods: Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF). The primary endpoint was overall survival (OS). Results: In the WHF group, the cumulative failure rate of hepatic arterial catheterization was 16.7% at 6 months. The occurrence of grade 3 adverse events was comparable between the groups. The 5-year OS rates were 59.0% in the CVI group and 34.9% in the WHF group (P = 0.164). CVI tended to show a protective effect against liver metastasis regarding the 5-year liver-specific cumulative recurrence rate: CVI, 45.0% vs. WHF, 68.3%; P = 0.037). Conclusion: HAI therapy has a certain protective effect against liver metastasis after curative resection in patients with colorectal cancer. However, this therapy did not contribute to any marked improvement in their overall survival.

KW - Adjuvant chemotherapy

KW - Colorectal cancer

KW - Hepatic arterial infusion

KW - Liver metastasis

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85019707924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019707924&partnerID=8YFLogxK

U2 - 10.4103/0973-1482.184524

DO - 10.4103/0973-1482.184524

M3 - Article

C2 - 28508838

AN - SCOPUS:85019707924

VL - 13

SP - 84

EP - 90

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

IS - 1

ER -